The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%. The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.
The economic slowdown has accentuated the fault lines already dividing the pharmaceutical world. Lack of innovation from the large pharma companies, coupled with the patent expiration precipice, has fueled merger and acquisition activity. The in-licensing deals that mirror this trend have been a positive boon for biotech companies with either promising compounds in their pipeline, or promising platforms – most especially for delivering RANi drugs, or uncovering pathways previously held within the domain of academia only.
As a shadow looming behind this field there have also been dramatic change to U.S. health policy through legislation, and the awakening of the increasingly alluring emerging markets in China and India – still small in comparison - but future engines for high growth.
BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our production of these research reports. This review of pharmaceutical market research conducted in 2010 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.
This review includes highlights from the following reports on pharmaceutical markets published BCC Research:
Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Global Markets for Orphan Drugs
Drug-Device Combinations: The Global Market
Cardiovascular Therapeutic Drugs: Technologies and Global Markets
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Antipsychotic Drugs: Technologies and Global Markets
Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
Oncology Adjuvants: Technologies and Global Markets
We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs